ArticleIranian journal of pharmaceutical research : IJPR
Mitigation of Cerebral Ischemia-Reperfusion Injury in Rat by Phellopterin via Antioxidant and Anti-inflammatory Mechanisms.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Naringin Administration Is Associated with Reduced Reproductive Toxicity Following Subchronic Low-Dose Chlorpyrifos Exposure in Rats.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral ischemia-reperfusion (I/R) injury is a significant pathological process in ischemic stroke, marked by oxidative stress, inflammation, and neuronal damage once blood flow is restored. Objectives: The present study investigates the neuroprotective effects of phellopterin, a natural coumarin derivative, in a rat model of cerebral I/R injury. Methods: The I/R injury was induced using the middle cerebral artery occlusion (MCAO) method, subjecting rats to 120 minutes of ischemia followed by 24 hours of reperfusion. Phellopterin was administered intragastrically at doses of 0.5 and 2.0 mg/kg, based on prior studies indicating effective therapeutic ranges in preclinical models. Neurological deficit scores (NDS) assessed functional impairments. Molecular markers of oxidative stress, including malondialdehyde (MDA) and superoxide dismutase (SOD), alongside inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), were measured using enzyme-linked immunosorbent assays (ELISA). Gene expression analysis utilized quantitative reverse transcription polymerase chain reaction (RT-PCR) to evaluate mRNA levels of key oxidative stress and inflammatory markers. Results: Our results indicated that phellopterin significantly reduced NDS in a dose-dependent manner. Molecular analyses demonstrated decreased MDA levels and increased SOD activity, reflecting reduced oxidative damage, alongside lowered TNF-α and IL-6 levels, indicating suppressed inflammation. The RT-PCR confirmed the upregulation of antioxidant genes [nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1)] and downregulation of pro-inflammatory genes [nuclear factor kappa B (NF-κB), iNOS]. Conclusions: In conclusion, phellopterin exhibits dual antioxidant and anti-inflammatory effects, suggesting its potential as a therapeutic agent for ischemic stroke. These findings underscore the potential of phellopterin as a promising candidate for the development of new treatments for ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.